There has been no experience of overdosage in human clinical trials.

Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:

Active internal bleeding

Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance.

History of cerebrovascular accident (CV A) within two years, or CV A with a significant residual neurological deficit

Bleeding diathesis

Administration of oral anticoagulants within seven days unless prothrombin time is <1.2 times control

Thrombocytopenia (<100 000 cells/m L)

Recent (within six weeks) major surgery or trauma

Intracranial neoplasm, arteriovenous malformation, or aneurysm

Severe uncontrolled hypertension

Presumed or documented history of vasculitis

Use of intravenous dextran before PC I, or intent to use it during an intervention Abciximab is also contraindicated in patients with known hypersensitivity to any component of this product or to murine proteins.

Bookmark this page: